Overall impact
B (77)

Commentary

Daxor is a strong overall performer. With a 'B' rating of 76.6 for overall impact (91st percentile compared to all companies), Daxor ranks 11th out of 103 industry peers, behind Endologix, Biostage, PetVivo and 7 others, and ahead of Waters, MyMD Pharmaceuticals, Alphatec and 89 others. On top material causes for Daxor's industry (Healthcare Equipment), Daxor performs well in Reduced Waste (88.1 score), Humane Treatment of Animals (92.8), Child and Maternal Health (95.0) and 6 other causes where it received an 'A' score. Daxor did not receive a 'D' or 'F' rating on any cause.
Impact
Cause DXR
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
1971
Employees
750
Sector
Health Care
Industry
Health Care Equipment & Supplies
Sub-industry
Health Care Supplies
SASB industry
Medical Equipment & Supplies
Headquarters
Tn, United States
Share classes
DXR
Description
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets the BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for use in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of the Estate of Joseph Feldschuh.
Material causes
Ethos considers the following causes material for Daxor, based on its industry sub-industry Health Care Supplies. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.